Execution Risks In Diabetes Automation Will Test Long Runway For Future Margin Expansion

Catalysts

About Insulet

Insulet develops and sells the Omnipod automated insulin delivery system for people living with diabetes.

What are the underlying business or industry changes driving this perspective?

• Although Omnipod 5 is gaining share in a U.S. type 1 market where AID use is 40% versus roughly 70% for CGM, closing that gap requires continued education of prescribers and payers. Slower adoption than expected could limit the benefit to recurring Pod revenue and temper operating margin expansion.
• Although type 2 adoption is picking up from a low base with AID use below 5% in a market size above US$12b, primary care physicians may face workflow and training constraints even with guideline support. This could restrain the pace of type 2 growth and soften the impact on total revenue and earnings.
• Although the upcoming fully closed loop system for type 2 is intended to remove dosing and setting complexity and is backed by EVOLUTION clinical work, any delay in pivotal studies, regulatory review or provider comfort could push out broader uptake. This could slow the expected contribution to long term revenue growth and gross margin scale.
• Although international markets show traction with Omnipod 5 launches, reimbursement wins and transitions from Omnipod DASH supporting price and mix, lower AID penetration at roughly 25% versus about 65% CGM use may persist if funding and health system capacity lag. This could moderate international revenue and limit further operating margin leverage.
• Although Insulet is investing about US$1b in R&D over three years and expanding manufacturing in Malaysia and Costa Rica to support volume and automation, execution risks in scaling facilities and integrating new algorithms like Omnipod 6 and additional CGM partners could pressure gross margins and near term earnings if productivity targets are not met.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Insulet compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Insulet's revenue will grow by 10.1% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 12.3% today to 16.8% in 3 years time.
• The bearish analysts expect earnings to reach $682.2 million (and earnings per share of $9.69) by about August 2029, up from $375.3 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $786.1 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 17.5x on those 2029 earnings, down from 26.7x today. This future PE is lower than the current PE for the US Medical Equipment industry at 26.3x.
• The bearish analysts expect the number of shares outstanding to decline by 1.48% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.66%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Automated insulin delivery usage in type 1 diabetes is already at 40% in the U.S., and management points to anniversarying large 2025 launches and tougher comparisons in 2026, so if AID penetration increases more slowly than expected or the pool of multiple daily injection conversions starts to mature, Omnipod new customer starts could slow and revenue growth could move below the current 20% to 23% Omnipod guidance, pressuring earnings growth.
• The type 2 diabetes opportunity is described as a more than US$12b market with AID penetration below 5% and primary care as the main prescriber base, but this requires busy non-specialist clinicians to adopt new workflows and training, so if guideline support and sampling programs do not materially change long term behavior, type 2 adoption could stay limited and the mix shift that currently supports recurring Pod revenue and operating margin expansion could stall, affecting earnings.
• International markets are framed as a long runway, with AID penetration at roughly 25% versus about 65% for CGM outside the U.S. and Omnipod 5 in 19 countries, yet reimbursement, health system capacity and pricing policies vary widely, so slower funding decisions, tighter pricing or delayed launches in new geographies like Spain and the Middle East could cap international revenue growth and reduce the contribution to gross margin and operating margin.
• Management plans to spend about US$1b on R&D over three years, expand manufacturing in Malaysia and build a new plant in Costa Rica that is expected to be operational in 2029, and is also ramping AI and data platforms, so any execution issues in scaling production, integrating new algorithms such as Omnipod 6 or the fully closed loop type 2 system, or delays in studies like STRIVE and EVOLUTION could raise costs, dampen gross margin expansion and slow adjusted EPS growth.
• The company highlights strong financial flexibility with 71.6% gross margin in 2025, free cash flow of more than US$375m and a large share repurchase authorization, but this sits alongside higher net interest expense of US$24.7m from debt refinancing and planned capex for global manufacturing, so if free cash flow stays flat beyond 2026 or interest and tax optimization do not offset spending, there could be less room for continued margin expansion and EPS growth than current commentary implies.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Insulet is $144.0, which represents up to two standard deviations below the consensus price target of $171.91. This valuation is based on what can be assumed as the expectations of Insulet's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $275.0, and the most bearish reporting a price target of just $144.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $4.1 billion, earnings will come to $682.2 million, and it would be trading on a PE ratio of 17.5x, assuming you use a discount rate of 7.7%.
• Given the current share price of $144.7, the analyst price target of $144.0 is 0.5% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.